These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Review article: chronic active disease and maintaining remission in Crohn's disease. Kamm MA Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():102-5. PubMed ID: 15352904 [TBL] [Abstract][Full Text] [Related]
6. Severe and steroid-resistant Crohn's disease. Michetti P; Mottet C; Juillerat P; Felley C; Vader JP; Burnand B; Gonvers JJ; Froehlich F Digestion; 2005; 71(1):19-25. PubMed ID: 15711044 [TBL] [Abstract][Full Text] [Related]
7. Maintenance therapy in Crohn's disease. Steinhart H Can J Gastroenterol; 2000 Sep; 14 Suppl C():23C-28C. PubMed ID: 11023557 [TBL] [Abstract][Full Text] [Related]
8. Transcending conventional therapies: the role of biologic and other novel therapies. Sandborn WJ Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043 [TBL] [Abstract][Full Text] [Related]
9. Severe and steroid-resistant Crohn's disease. Michetti P; Mottet C; Juillerat P; Pittet V; Felley C; Vader JP; Gonvers JJ; Froehlich F Digestion; 2007; 76(2):99-108. PubMed ID: 18239400 [TBL] [Abstract][Full Text] [Related]
10. Methotrexate for induction of remission in refractory Crohn's disease. Alfadhli AA; McDonald JW; Feagan BG Cochrane Database Syst Rev; 2005 Jan; (1):CD003459. PubMed ID: 15674908 [TBL] [Abstract][Full Text] [Related]
11. Review article: the limitations of corticosteroid therapy in Crohn's disease. Rutgeerts PJ Aliment Pharmacol Ther; 2001 Oct; 15(10):1515-25. PubMed ID: 11563990 [TBL] [Abstract][Full Text] [Related]
12. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease. Gelbmann CM; Rogler G; Gross V; Gierend M; Bregenzer N; Andus T; Schölmerich J Am J Gastroenterol; 2002 Jun; 97(6):1438-45. PubMed ID: 12094862 [TBL] [Abstract][Full Text] [Related]
13. Methotrexate for induction of remission in refractory Crohn's disease. Alfadhli AA; McDonald JW; Feagan BG Cochrane Database Syst Rev; 2003; (1):CD003459. PubMed ID: 12535475 [TBL] [Abstract][Full Text] [Related]
14. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease. Lichtenstein GR Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S23-9. PubMed ID: 11380040 [TBL] [Abstract][Full Text] [Related]
15. Mild to moderate Crohn's disease: still room for step-up therapies? Bar-Meir S Dig Dis; 2009; 27(3):347-50. PubMed ID: 19786763 [TBL] [Abstract][Full Text] [Related]
16. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease. Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302 [TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil in patients with Crohn's disease. Fickert P; Hinterleitner TA; Wenzl HH; Aichbichler BW; Petritsch W Am J Gastroenterol; 1998 Dec; 93(12):2529-32. PubMed ID: 9860419 [TBL] [Abstract][Full Text] [Related]
18. [Internistic therapy possibilities in therapy-resistant Crohn disease]. Hoffmann R Schweiz Rundsch Med Prax; 1992 Jun; 81(26):866-8. PubMed ID: 1626163 [TBL] [Abstract][Full Text] [Related]
19. [Anti-TNF therapy in treatment of luminal Crohn's disease]. Marko B; Prka L Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301 [TBL] [Abstract][Full Text] [Related]
20. Maintenance of remission in Crohn's disease. Gonvers JJ; Juillerat P; Mottet C; Felley C; Burnand B; Vader JP; Michetti P; Froehlich F Digestion; 2005; 71(1):41-8. PubMed ID: 15711049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]